Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints Ozempic and Wegovy maker lost $94.5 billion in market value after releasing study results for a next-generation weight-loss …

CouponFollow Extension

$94
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

3 weeks from now

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints Ozempic and Wegovy maker lost $94.5 billion in market value after releasing study results for a next-generation weight-loss …

wsj.com

7%
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

3 weeks from now

CagriSema’s 22.7% reduction, while large and higher than the 2.3% among people getting a placebo, fell short of the 25% weight loss Novo Nordisk had expected. The company said the …

msn.com

20%
OFF

Novo Nordisk Shares Plunge 20% After Disappointing Trial Results; …

3 weeks from now

Dec 20, 2024 · Shares of Novo Nordisk plummeted roughly 20% on Friday. The fall comes after the Danish pharmaceutical giant reported results in a late-stage trial for its experimental …

nbcchicago.com

4%
OFF

Novo Nordisk Falls Most On Record After New Weight Drug …

3 weeks from now

Dec 20, 2024 · The shot helped patients lose an average of 20.4% of their weight over 68 weeks, short of the 25% weight loss that Novo had predicted for its next-generation product, which …

moneycontrol.com

4%
OFF

Novo Nordisk Shares Plunge Obesity Drug Disappoints - Bloomberg

3 weeks from now

Dec 20, 2024 · The shot helped patients lose an average of 20.4% of their weight over 68 weeks, short of the 25% weight loss that Novo had predicted for its next-generation product, which …

bloomberg.com

25%
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Falls Short Of ...

3 weeks from now

Dec 20, 2024 · The outcome falls short of the 25% weight loss Novo Nordisk had expected and dents its chances of becoming the company's next blockbuster drug after Ozempic and …

marketscreener.com

20%
OFF

Novo Nordisk Stock Plunges After Disappointing Obesity

3 weeks from now

Dec 20, 2024 · Shares in Danish drug maker Novo Nordisk , known for its blockbuster drugs Ozempic and Wegovy, fell roughly 20% on Friday after it released the results of a clinical trial …

morningstar.co.uk

€90
OFF

Novo Nordisk Shares Tumble As Data On Weight-loss Drug Trial …

3 weeks from now

Dec 20, 2024 · Novo Nordisk’s shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90bn off the valuation of Europe’s largest company by …

ft.com

7%
OFF

Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial …

3 weeks from now

Dec 20, 2024 · The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Novo's shares fell as much as 27% after the …

yahoo.com

20%
OFF

Novo Nordisk Shares Plunge On The Back Of Disappointing

3 weeks from now

Dec 23, 2024 · Novo Nordisk has announced its latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark …

euronews.com

7%
OFF

Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial ...

3 weeks from now

Dec 21, 2024 · The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Novo's shares fell as much as 27% after the …

indiatimes.com

$125
OFF

Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial ...

3 weeks from now

Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its …

reuters.com

18%
OFF

Novo Nordisk Stock Crashes 18% After New Obesity Drug Misses …

3 weeks from now

Dec 20, 2024 · Novo Nordisk Stock Slumps. The bad news sent Novo Nordisk stock down 17.8% to 85. Shares have been falling since midyear. Eli Lilly stock rose 1.4% to 767.76, while Viking …

investors.com

5%
OFF

Novo Nordisk Shares Drop Nearly 5% On Disappointing Obesity Pill …

3 weeks from now

Sep 20, 2024 · LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill …

yahoo.com

20%
OFF

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk …

3 weeks from now

Dec 20, 2024 · Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted. ... Shares of Novo Nordisk were down …

benzinga.com

2%
OFF

Novo Nordisk Shares Plummet After Weight-loss Drug’s …

3 weeks from now

Dec 20, 2024 · Shares in US rival Lilly rose 2%. ‘Worst-case scenario’ Novo said if all people adhered to treatment with CagriSema, patients overall achieved weight loss of 22.7% after 68 …

nypost.com

FAQs about Novo Nordisk Shares Plunge After New Obesity Shot Disappoints Coupon?

Is Novo Nordisk launching a weight loss drug?

It expects to begin that trial next year, according to its statement. With Wegovy, Novo Nordisk was first-to-market with a highly-effective weight loss medication from a drug class known as GLP-1 receptor agonists. U.S. rival Eli Lilly is the only other company with an obesity drug from the same class. ...

Why did Novo Nordisk's shares fall?

Novo Nordisk’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ability to maintain its lead in the exploding weight-loss market. ...

Why did Novo Nordisk stock tank?

Novo Nordisk's stock tanked after a highly anticipated drug trial disappointed. The study showed its new obesity drug helped people lose less weight than expected. Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%. ...

Why did Novo Nordisk stock plunge?

(Photo: Reuters/Tom Little) COPENHAGEN: Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday (Dec 20) after it announced disappointing results of a new drug study. ...

Why did Novo Nordisk A/S stock fall by the most on record?

Novo Nordisk A/S ’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. ...

Does Novo Nordisk anti-obesity treatment help patients lose weight?

A n experimental Novo Nordisk anti-obesity treatment helped patients lose less than a quarter of their bodyweight in a new study, missing the company’s expectations and sending its shares sharply lower. ...